Global Health Council role in new USTR/DHHS reveiw of 301?

[James Love <love@cptech.org>]

---------------
In a somewhat surprising move, the Clinton Administration is considering
giving the US based Global Health Council an important role the new
public health reviews of 301 action.  This is surprising because (a) GHC
has no particular expertise in trade or IPR issues, (b) it has been
actively opposing the campaign for access, telling members of Congress
and the news media it won't help patients and will potentially harm the
public health, and (c) it has close ties to the big PhRMA companies.  

According to its web page, here are the GGHC's board of directors:


Board of Directors -GHC 

Emerling, Carol, L.L.B., Chair, American Home Products Corporation
Strickler, James M.D., Vice Chair, Dartmouth University Medical School
Lamstein, Joel, S.M., Treasurer, President, John Snow, Inc., President,
        World Education
Daulaire, Nils, M.D., M.P.H., Secretary, President & CEO Global Health
        Council
Black, Robert, M.D., M.P.H., Johns Hopkins University School of Hygiene
        and Public Health
Foege, William, M.D., M.P.H., Emory University Department of
        International Health
Gayle, Helene, M.D., M.P.H., Director, National Center for HIV, STD and
        TB Prevention
Mahmoud, Adel, M.D., Ph.D., President, Merck Vaccines, Merck & Company,
        Inc.
Nelson, Jean J.D., Former General Counsel, Environmental Protection
        Agency
Pillsbury, Barbara, Ph.D., Co-Founder and Director, Pacific Institute
        for Women's Health


-- 
James Love / Director, Consumer Project on Technology
http://www.cptech.org / love@cptech.org
P.O. Box 19367, Washington, DC 20036
voice 202.387.8030 / fax 202.234.5176